HM Payson & Co’s BeOne Medicines Ltd ONC Stock Holding History

HM Payson & Co’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2	Closed	-$682	–	1216
2025 Q3	$682	Buy	+2	New	+$607	﹤0.01%	1059

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

HM Payson & Co's ONC Position: Q4 2025 in Review

HM Payson & Co sold out of BeOne Medicines Ltd (ONC) in Q4 2025, closing a stake of 2 shares — an estimated $682 sold.

HM Payson & Co first reported a position in ONC in Q3 2025 and held it in 1 quarter. The position peaked at $682 in Q3 2025. 286 funds tracked by Wall St. Rank hold ONC as of Q4 2025.

HM Payson & Co reported no remaining BeOne Medicines Ltd position as of Q4 2025 after selling out during the quarter.
HM Payson & Co sold 2 BeOne Medicines Ltd shares in Q4 2025, an estimated $682.
HM Payson & Co first reported a position in BeOne Medicines Ltd in Q3 2025 and held it in 1 quarter.
HM Payson & Co's BeOne Medicines Ltd position peaked at $682 in Q3 2025.
286 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q4 2025.

Based on HM Payson & Co's 13F filing for Q4 2025, filed 12 Feb 2026.